[go: up one dir, main page]

AR129268A1 - Anticuerpo que se une a vegf-a e il6 y métodos de uso - Google Patents

Anticuerpo que se une a vegf-a e il6 y métodos de uso

Info

Publication number
AR129268A1
AR129268A1 ARP230101134A ARP230101134A AR129268A1 AR 129268 A1 AR129268 A1 AR 129268A1 AR P230101134 A ARP230101134 A AR P230101134A AR P230101134 A ARP230101134 A AR P230101134A AR 129268 A1 AR129268 A1 AR 129268A1
Authority
AR
Argentina
Prior art keywords
amino acid
seq
acid sequence
cdr
antibody
Prior art date
Application number
ARP230101134A
Other languages
English (en)
Inventor
Roland Beckmann
Joerg Benz
Davide Bertoldo
Faye Marie Drawnel
Derrick Feenstra
Sebastian Fenn
Stefan Frost
Marlon Hinner
Kristian Hobolt Jensen
Daniela Matscheko
Anastasia Meier
Oliver Ploettner
Janina Speck
Pamela Strassburger
Barbara Marie Weiser
- Widmer Gabriella Luise
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR129268A1 publication Critical patent/AR129268A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos anti-VEGF-A / anti-IL6, por ejemplo, en forma de un fragmento Fab biespecífico, y sus métodos de uso. Reivindicación 1: Un anticuerpo que se une a VEGF-A humano y a IL6 humana que comprende un dominio VH que comprende (a) CDR-H1 que comprende la secuencia de aminoácidos de SEQ ID Nº 18, (b) CDR-H2 que comprende la secuencia de aminoácidos de SEQ ID Nº 19 y (c) CDR-H3 que comprende la secuencia de aminoácidos de SEQ ID Nº 20, y un dominio VL que comprende (d) CDR-L1 que comprende la secuencia de aminoácidos de SEQ ID Nº 15, (e) CDR-L2 que comprende la secuencia de aminoácidos de SEQ ID Nº 16 y (f) CDR-L3 que comprende la secuencia de aminoácidos de SEQ ID Nº 17, que comprende un dominio variable de la cadena pesada que comprende una secuencia de aminoácidos de SEQ ID Nº 22 con hasta 5 sustituciones de aminoácidos; y un dominio variable de la cadena liviana que comprende una secuencia de aminoácidos de SEQ ID Nº 21 con hasta 5 sustituciones de aminoácidos. Reivindicación 9: Un ácido nucleico aislado que codifica el anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 a 8. Reivindicación 12: El método de acuerdo con la reivindicación 11, en donde la célula huésped es una célula CHO. Reivindicación 16: Un dispositivo de administración de boquilla que comprende el anticuerpo de cualquiera de las reivindicaciones 1 a 8 o la formulación farmacéutica de acuerdo con la reivindicación 13.
ARP230101134A 2022-05-11 2023-05-09 Anticuerpo que se une a vegf-a e il6 y métodos de uso AR129268A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22172759 2022-05-11

Publications (1)

Publication Number Publication Date
AR129268A1 true AR129268A1 (es) 2024-08-07

Family

ID=81603574

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101134A AR129268A1 (es) 2022-05-11 2023-05-09 Anticuerpo que se une a vegf-a e il6 y métodos de uso

Country Status (16)

Country Link
US (1) US20250163139A1 (es)
EP (1) EP4522648A1 (es)
JP (1) JP7801491B2 (es)
KR (1) KR20250008903A (es)
CN (1) CN119173529A (es)
AR (1) AR129268A1 (es)
AU (1) AU2023267952A1 (es)
CA (1) CA3256863A1 (es)
CL (1) CL2024003373A1 (es)
CO (1) CO2024015714A2 (es)
CR (1) CR20240473A (es)
IL (1) IL316326A (es)
MX (1) MX2024013703A (es)
PE (1) PE20251283A1 (es)
TW (1) TW202402810A (es)
WO (1) WO2023217933A1 (es)

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU757627B2 (en) 1997-06-24 2003-02-27 Genentech Inc. Methods and compositions for galactosylated glycoproteins
JP2001521909A (ja) 1997-10-31 2001-11-13 ジェネンテク・インコーポレイテッド 糖タンパク質グリコフォームを含む方法及び組成物
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
AU5070899A (en) 1998-07-23 2000-02-14 Cooperatieve Verkoop- En Productievereniging Van Aardappelmeel En Derivaten Avebe B.A. Adhesive composition
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100887482B1 (ko) 1999-01-15 2009-03-10 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
UA89350C2 (uk) 2002-12-16 2010-01-25 Дженентек, Інк. Гуманізоване антитіло, що зв'язує людський cd20
ATE475708T1 (de) 2003-01-22 2010-08-15 Glycart Biotechnology Ag Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
NZ549872A (en) 2004-04-13 2009-09-25 Hoffmann La Roche Anti-P-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
UA95068C2 (uk) 2005-02-07 2011-07-11 Глікарт Біотехнолоджі Аг Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
US20110059101A9 (en) * 2006-03-13 2011-03-10 Ablynx N.V. Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
SG2014007389A (en) 2009-01-29 2014-04-28 Forsight Vision4 Inc Posterior segment drug delivery
JP2013534520A (ja) 2010-06-08 2013-09-05 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
HRP20211909T1 (hr) 2010-08-05 2022-03-18 Forsight Vision4, Inc. Uređaj za liječenja oka
EP2600920A4 (en) 2010-08-05 2017-10-04 Forsight Vision4, Inc. Subconjunctival implant for posterior segment drug delivery
FI2691417T4 (fi) 2011-03-29 2025-01-14 Roche Glycart Ag Vasta-aineen Fc-variantteja
US20140206846A1 (en) 2011-05-27 2014-07-24 Roland Beckmann Dual Targeting
DK2755600T3 (da) 2011-09-16 2021-05-03 Forsight Vision4 Inc Fluidudvekslingsindretning
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
TR201808458T4 (tr) 2012-02-15 2018-07-23 Hoffmann La Roche FC-reseptör bazlı afinite kromatografisi.
BR112015010360A8 (pt) 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
AU2014261630B2 (en) 2013-04-29 2019-05-09 F. Hoffmann-La Roche Ag Human FcRn-binding modified antibodies and methods of use
WO2015085234A1 (en) 2013-12-06 2015-06-11 Forsight Vision4, Inc. Implantable therapeutic devices
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
WO2016016299A1 (en) 2014-07-29 2016-02-04 F. Hoffmann-La Roche Ag Multispecific antibodies
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
EP4126940A1 (en) 2020-03-30 2023-02-08 F. Hoffmann-La Roche AG Antibody that binds to vegf and pdgf-b and methods of use

Also Published As

Publication number Publication date
WO2023217933A1 (en) 2023-11-16
AU2023267952A1 (en) 2024-10-31
US20250163139A1 (en) 2025-05-22
PE20251283A1 (es) 2025-05-14
CO2024015714A2 (es) 2025-04-16
JP7801491B2 (ja) 2026-01-16
CA3256863A1 (en) 2023-11-16
TW202402810A (zh) 2024-01-16
JP2025521085A (ja) 2025-07-08
EP4522648A1 (en) 2025-03-19
CR20240473A (es) 2025-01-06
KR20250008903A (ko) 2025-01-16
CN119173529A (zh) 2024-12-20
IL316326A (en) 2024-12-01
MX2024013703A (es) 2024-12-06
CL2024003373A1 (es) 2025-03-14

Similar Documents

Publication Publication Date Title
AR110659A1 (es) Proteínas de unión a antígenos anti-neuropilin y método para su uso
PE20230408A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
PE20221511A1 (es) Anticuerpos anti-ly6g6d y metodos de uso
PE20211605A1 (es) ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS
PE20181952A1 (es) Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
AR106991A1 (es) Anticuerpos neutralizantes del virus de inmunodeficiencia humana
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
CN104903352A (zh) 多价结合蛋白组合物
PE20210554A1 (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
PE20220763A1 (es) Materiales y metodos para modular la inmunidad mediada por celulas t
PE20231504A1 (es) Anticuerpos especificos para kras y sus usos
PE20181051A1 (es) Anticuerpo anti-epha4
CO6311009A2 (es) Anticuerpos monoclonales anti-cd151 de origen murino quimericos y humanizados para inhibir el crecimiento tumoral, secuencias de aminoacidos y nucleicos que los codifican, compuestod derivados o fragmentos funcionales y productos y/o composiciones qu
PE20251639A1 (es) Anticuerpos que se unen a interleuquina 13 y metodos de uso
AR123306A1 (es) Anticuerpos fgfr3 y métodos de uso
MX2024012479A (es) Anticuerpos anti-tl1a y metodos de uso de los mismos
PE20230414A1 (es) Agentes de fijacion a tie2 y metodos de uso
AR129268A1 (es) Anticuerpo que se une a vegf-a e il6 y métodos de uso
PE20250390A1 (es) Anticuerpos anti-c3 y fragmentos de union al antigeno de estos y sus usos para tratar enfermedades oftalmicas u oculares
PE20231300A1 (es) Anticuerpos anti-notch2 y metodos de uso
AR125074A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
AR124019A1 (es) Construcciones polipeptídicas que se unen a cd3
AR129472A1 (es) Anticuerpos anti-bcma